What Does The Negative FDA Review For Intercept’s OCA Hold For Other NASH Drugs?

 
• By Joseph Haas
Comparative analysis
Analysts saw FDA panel as bad news for FXR agonists, but not other NASH classes • Source: Shutterstock

More from New Products

More from Scrip